KYORIN Pharmaceutical (4569) · InitiativeDropped
Launch of the Phase I Clinical Trial for KRP-A218 in the United Kingdom
First written in FY2022-Q1. 1 of 3 entries say "Restated". Latest entry: FY2026-H1.
3entries
5years
0from disclosures
How it moved
Same theme, other companies
Phase I clinical trial and development discontinuation for KRP-A218 for rhinovirus infectionA theme 1 companies write about · 1 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2026-H1DroppedAnnual report
「Development of KRP-A218, a treatment for rhinovirus infection, was discontinued for strategic reasons.」
For KRP-A218, discontinuation of development for strategic reasons was disclosed following the initiation of the Phase I clinical trial in the UK. - FY2022-Q2RestatedAnnual report
「We began a Phase I clinical trial in the United Kingdom in April of that year in healthy adults for KRP-A218, a treatment for rhinovirus infection in patients at risk of severe disease.」
The company continues to report that a Phase I clinical trial in healthy adults was initiated in the UK for KRP-A218. - FY2022-Q1First statedAnnual report
「We began a Phase I clinical trial in the United Kingdom in April of that year in healthy adults for KRP-A218, a treatment for rhinovirus infection in patients at risk of severe disease.」
A Phase I clinical trial of KRP-A218 in healthy adults began in the United Kingdom.